{"organizations": [], "uuid": "61c824256b020f77f5b6f8de3421536c2bacc80c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-acceleron-plans-to-initiate-part-2/brief-acceleron-plans-to-initiate-part-2-of-ace-083-fshd-phase-2-trial-during-q2-of-2018-idUSASB0C04M", "country": "US", "domain_rank": 408, "title": "BRIEF-Acceleron plans to initiate part 2 of ACE-083 FSHD phase 2 trial during Q2 of 2018", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-08T16:18:00.000+02:00", "replies_count": 0, "uuid": "61c824256b020f77f5b6f8de3421536c2bacc80c"}, "author": "", "url": "https://www.reuters.com/article/brief-acceleron-plans-to-initiate-part-2/brief-acceleron-plans-to-initiate-part-2-of-ace-083-fshd-phase-2-trial-during-q2-of-2018-idUSASB0C04M", "ord_in_thread": 0, "title": "BRIEF-Acceleron plans to initiate part 2 of ACE-083 FSHD phase 2 trial during Q2 of 2018", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters staff", "sentiment": "none"}, {"name": "acceleron pharma inc", "sentiment": "none"}, {"name": "acceleron pharma inc", "sentiment": "none"}, {"name": "acceleron", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 18 PM / in 6 minutes BRIEF-Acceleron plans to initiate part 2 of ACE-083 FSHD phase 2 trial during Q2 of 2018 Reuters Staff 1 Min Read \nJan 8 (Reuters) - Acceleron Pharma Inc: \n* ACCELERON PHARMA INC - PLANS TO INITIATE PART 2 OF ACE-083 FSHD PHASE 2 TRIAL DURING Q2 OF 2018 \n* ACCELERON ANNOUNCES PRELIMINARY RESULTS FROM PART 1 OF THE ACE-083 PHASE 2 TRIAL IN PATIENTS WITH FACIOSCAPULOHUMERAL DYSTROPHY Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-08T16:18:00.000+02:00", "crawled": "2018-01-08T16:33:58.019+02:00", "highlightTitle": ""}